ARDS, Human, Covid19, Hemodynamic Instability
Conditions
Keywords
COVID, hemodynamic monitoring, ARDS
Brief summary
The aim of the present work is to describe the hemodynamic effects shown in patients with ARDS secondary to SARS-CoV-2 infection
Interventions
None listed
Sponsors
Edwards Lifesciences
Juan Victor Lorente
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients over 18 years old. * Patients that are classified as a confirmed case according to criteria established by the Spanish Ministry of Health in its Technical Document updated on March 31, 2020. This defines a confirmed case as a case that meets laboratory criteria (Positive PCR test for any of the SARS-CoV-2 genes). * Patients admitted to ICU. * Presence of Kirby index (PaFi) less than or equal to 300 mm Hg, with PEEP or CPAP greater than or equal to 5 cmH2O. * Need for radial artery cannulation for hemodynamic monitoring and/or repeated monitoring of blood gases at the discretion of the responsible physician. * Patients who agree (or a representative of the patient if sedated) to participate in study and who provide written informed consent.
Exclusion criteria
* Patients being treated with veno-venous or veno-arterial ECMO * Patient with therapeutic restrictions due to life support * Patient who presents a complication that requires surgical intervention.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total amount of hypotension | 5 days | Hypotension will be defined as a hemodynamic event that occurs when the MAP falls below 65 mmHg for a minimum duration of 1 minute (3 consecutive recordings of 1 minute or more between two consecutive falls of the MAP). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Minimally invasive hemodynamic monitoring and related variables obteined from HemoSphere platform with Acumen IQ sensor (Stroke volume variation) | 5 days | We will obtain hemodynamic data for the first 5 days after the patient enters the study |
| Minimally invasive hemodynamic monitoring and related variables obteined from HemoSphere platform with Acumen IQ sensor (Cardiac index) | 5 days | We will obtain hemodynamic data for the first 5 days after the patient enters the study |
| Minimally invasive hemodynamic monitoring and related variables obteined from HemoSphere platform with Acumen IQ sensor ( HPI) | 5 days | We will obtain hemodynamic data for the first 5 days after the patient enters the study |
| Minimally invasive hemodynamic monitoring and related variables obteined from HemoSphere platform with Acumen IQ sensor (Eadyn) | 5 days | We will obtain hemodynamic data for the first 5 days after the patient enters the study |
| Minimally invasive hemodynamic monitoring and related variables obteined from HemoSphere platform with Acumen IQ sensor (dp/dt max,) | 5 days | We will obtain hemodynamic data for the first 5 days after the patient enters the study |
| Presence of treatment with noradrenaline; presence of treatment with dobutamine, presence of treatment with other vasoactive/ionotropic/hypotensive drugs | 5 days | start time, time of dose change, current dose |
| Furosemide treatment | Daily during 5 days | dose/24 hours |
| Minimally invasive hemodynamic monitoring and related variables obteined from HemoSphere platform with Acumen IQ sensor (Stroke volume) | 5 days | We will obtain hemodynamic data for the first 5 days after the patient enters the study |
| Atrial fibrillation | 5 days | Presence, start time and end time |
| Acute kidney injury | Daily during 5 days | Presence and degree with KDIGO definition |
| Continuous renal replacement therapies | 5 days | Start and end date/time, dialyzing flow, replacement flow, daily balance. |
| Need for Hemadsorption | 5 days | Start and end date/time, blood flow. |
| Specific treatment for SARS-CoV2 (presence of tocilizumab, antimalarial drugs, antivirals) | 5 days | Start and end date/time |
| Corticoid treatment. | 5 days | Start and end date/time |
| Daily diuresis, daily water balance, accumulated water balance since ICU admission, daily parenteral nutrition volume, and daily enteral nutrition volume. | Daily during 5 days | ml/24 h |
Countries
Spain
Contacts
Primary ContactJuan Victor Lorente, MD
Outcome results
None listed